全文获取类型
收费全文 | 5545篇 |
免费 | 490篇 |
国内免费 | 360篇 |
专业分类
耳鼻咽喉 | 42篇 |
儿科学 | 55篇 |
妇产科学 | 41篇 |
基础医学 | 595篇 |
口腔科学 | 58篇 |
临床医学 | 715篇 |
内科学 | 883篇 |
皮肤病学 | 75篇 |
神经病学 | 266篇 |
特种医学 | 203篇 |
外科学 | 718篇 |
综合类 | 946篇 |
预防医学 | 327篇 |
眼科学 | 147篇 |
药学 | 682篇 |
1篇 | |
中国医学 | 309篇 |
肿瘤学 | 332篇 |
出版年
2024年 | 3篇 |
2023年 | 94篇 |
2022年 | 116篇 |
2021年 | 249篇 |
2020年 | 185篇 |
2019年 | 189篇 |
2018年 | 185篇 |
2017年 | 166篇 |
2016年 | 166篇 |
2015年 | 245篇 |
2014年 | 274篇 |
2013年 | 306篇 |
2012年 | 398篇 |
2011年 | 394篇 |
2010年 | 252篇 |
2009年 | 207篇 |
2008年 | 267篇 |
2007年 | 365篇 |
2006年 | 298篇 |
2005年 | 304篇 |
2004年 | 200篇 |
2003年 | 206篇 |
2002年 | 163篇 |
2001年 | 133篇 |
2000年 | 150篇 |
1999年 | 134篇 |
1998年 | 93篇 |
1997年 | 90篇 |
1996年 | 79篇 |
1995年 | 84篇 |
1994年 | 53篇 |
1993年 | 29篇 |
1992年 | 33篇 |
1991年 | 41篇 |
1990年 | 35篇 |
1989年 | 47篇 |
1988年 | 32篇 |
1987年 | 24篇 |
1986年 | 25篇 |
1985年 | 7篇 |
1984年 | 12篇 |
1983年 | 9篇 |
1982年 | 3篇 |
1981年 | 5篇 |
1980年 | 4篇 |
1978年 | 3篇 |
1977年 | 8篇 |
1973年 | 4篇 |
1971年 | 4篇 |
1969年 | 3篇 |
排序方式: 共有6395条查询结果,搜索用时 31 毫秒
2.
目的 通过网络药理学的方法进行预测,再深一步进行动物实验验证来研究柴胡疏肝散治疗CAG的作用机制。方法 首先在TCMSP数据库中检索柴胡疏肝散的所有活性成分与药物靶点;通过收集PharmGkb、OMIM、GeneCards和DrugBank数据库中收录的慢性萎缩性胃炎的相关靶点。将药物靶点与疾病靶点进行映射筛选出交集靶点,将得到的交集靶点构建PPI网络与活性成分-共同靶点网络,并对其进行GO和KEGG富集分析。最后利用Vina软件进行分子对接实验验证,并通过免疫印迹法验证柴胡疏肝散对两种受体蛋白EGFR和STAT1的影响。结果 最终筛选得到柴胡疏肝散活性成分104个,潜在靶点238个,与慢性萎缩性胃炎的交集靶点52个;GO与KEGG富集分析分别得到2166条目和148条目,主要涉及到JAK-STAT信号通路、TNF信号通路、HIF-1信号通路等;分子对接结果显示EGFR、STAT1两个靶点能够与核心活性成分能够自发结合成较为稳定的构像;免疫印迹法实验证明柴胡疏肝散能够降低大鼠胃黏膜组织EGFR和STAT1蛋白表达。结论 通过网络药理学和实验验证,发现柴胡疏肝散可能通过调节EGFR和STAT1蛋白表达来共同调控胃黏膜细胞增殖与凋亡,进而发挥着治疗慢性萎缩性胃炎的效果,为深入进行柴胡疏肝散治疗慢性萎缩性胃炎的作用机制研究提供新思路和新方法。 相似文献
3.
4.
Jingjing Du Peiwen Zhang Jiang Luo Linyuan Shen Shunhua Zhang Hao Gu Jin He Linghui Wang Xue Zhao Mailing Gan Liu Yang Lili Niu Ye Zhao Qianzi Tang Guoqing Tang Dongmei Jiang Yanzhi Jiang Mingzhou Li Anan Jiang Long Jin Jideng Ma Surong Shuai Lin Bai Jinyong Wang Bo Zeng De Wu Xuewei Li Li Zhu 《Gut microbes》2021,13(1)
5.
6.
Yang Luan Yan Zhang Kai Cui Fan Li Baolong Qin Yajun Ruan Kun Tang Hongyang Jiang Hao Li Xiaoyi Yuan Zhuo Liu Xiaming Liu Gan Yu Shengfei Xu Ruibao Chen Huan Yang Xiaolin Guo Xiaoyong Zeng Zhong Chen Zhiqiang Chen Zhiquan Hu Xiaodong Song Zhihua Wang Shaogang Wang Jihong Liu Tao Wang 《Translational andrology and urology》2021,10(1):466
BackgroundTo introduce and determine the value of optimized strategies for the management of urological tube-related emergencies with increased incidence, complexity and operational risk during the global spread of coronavirus disease 2019 (COVID-19).MethodsAll emergent urological patients at Tongji Hospital, Wuhan, during the period of January 23 (the beginning of lockdown in Wuhan) to March 23, 2020, and the corresponding period in 2019 were recruited to form this study’s COVID-19 group and control group, respectively. Tongji Hospital has the most concentrated and strongest Chinese medical teams to treat the largest number of severe COVID-19 patients. Patients in the control group were routinely treated, while patients in the COVID-19 group were managed following the optimized principles and strategies. The case incidence for each type of tube-related emergency was recorded. Baseline characteristics and management outcomes (surgery time, secondary complex operation rate, readmission rate, COVID-19 infection rate) were analyzed and compared across the control and COVID-19 periods.ResultsThe total emergent urological patients during the COVID-19 period was 42, whereas during the control period, it was 124. The incidence of tube-related emergencies increased from 53% to 88% (P<0.001) during the COVID-19 period. In particular, the incidence of nephrostomy tube-related (31% vs. 15%, P=0.027) and single-J stent-related problems (19% vs. 6%, P=0.009) increased significantly. The mean surgery times across the two periods were comparable. The number of secondary complex operations increased from 12 (18%) to 14 (38%) (P=0.028) during the COVID 19-period. The number of 2-week postoperative readmission decreased from 10 (15%) to 1 (3%) (P=0.049). No participants contracted during the COVID-19 period.ConclusionsUrological tube-related emergencies have been found to have a higher incidence and require more complicated and dangerous operations during the COVID-19 pandemic. However, the optimized management strategies introduced in this study are efficient, and safe for both urologists and patients. 相似文献
7.
Qiong Na Zheng Mei Yan Xu Fang Min Gan Sha Sha Ye Hui Zhao 《World Journal of Clinical Cases》2021,9(16):4090-4094
BACKGROUNDThere are no effective antiviral therapies for coronavirus disease 2019 (COVID-19) at present. Although most patients with COVID-19 have a mild or moderate course of disease, up to 5%-10% of patients may have a serious and potentially life-threatening condition, indicating an urgent need for effective therapeutic drugs. The therapeutic effect of thymosin on COVID-19 has not been previously studied. In this paper, for the first time we report a case of thymosin treatment of COVID-19.CASE SUMMARYA 51-year-old man with imported COVID-19 was admitted with definite symptoms of chest tightness, chest pain, and fatigue. The polymerase chain reaction results for severe acute respiratory syndrome coronavirus 2 were negative. The antibody test was positive, confirming the diagnosis of COVID-19. As many orally administered drugs were not well tolerated due to gastrointestinal symptoms, an emergency use of thymosin, a polypeptide consisting of 28 amino acids, was administered by injection. Finally, after the implementation of the treatment program, symptoms and lung imaging improved significantly.CONCLUSIONIn this case report, it is confirmed that thymosin may help alleviate the severity of COVID-19 symptoms. 相似文献
8.
Jie Li Megan M. Kaneda Jun Ma Ming Li Ryan M. Shepard Kunal Patel Tomoyuki Koga Aaron Sarver Frank Furnari Beibei Xu Sanjay Dhawan Jianfang Ning Hua Zhu Anhua Wu Gan You Tao Jiang Andrew S. Venteicher Jeremy N. Rich Christopher K. Glass Judith A. Varner Clark C. Chen 《Proceedings of the National Academy of Sciences of the United States of America》2021,118(16)
9.
目的: 建立壮药材滇桂艾纳香专属性检验方法。方法: 采用基原鉴别、性状鉴别、显微鉴别、薄层鉴别、分子生物学及特征图谱等方法对滇桂艾纳香及其易混品种东风草和高艾纳香进行对比研究。结果: 三者的根、茎、叶性状基本相同,区别点在于滇桂艾纳香头状花序小(直径0.5~0.8 cm),东风草头状花序大(直径1.5~2 cm),高艾纳香头状花序具密集的长绒毛;三者的根、茎横切面,粉末显微特征基本相同,高艾纳香具基部膨大的非腺毛;薄层鉴别(1)中高艾纳香比滇桂艾纳香和东风草少1个斑点;薄层鉴别(2)中滇桂艾纳香比东风草和高艾纳香少1个特征斑点;ITS2序列N-J树聚类分析显示三者具有良好的单系性,三者种间最小遗传距离均大于种内最大遗传距离;与滇桂艾纳香对照图谱相比,东风草平均相似度为0.962,高艾纳香平均相似度仅为0.789。结论: 高艾纳香与滇桂艾纳香区别较大,不宜混用,在日常使用中应注意甄别;东风草与滇桂艾纳香在性状、显微、薄层、分子生物学、特征图谱等方面相似度较高,在对二者进行充分的药理活性以及临床试验等基础上,可考虑作为滇桂艾纳香的替代品使用,以缓解药用资源不足的问题。 相似文献
10.